上海海利生物技術股份有限公司
控股子公司楊凌金海生物技術有限公司與
禮藍（上海）動物保健有限公司
簽訂《獨家推廣協(xié)議》
2019年8月20日，海利生物（股票代碼：603718.SH）控股子公司楊凌金海生物技術有限公司（以下簡稱“楊凌金?！保┡cElanco US Inc.的子公司禮藍（上海）動物保健有限公司（以下簡稱“禮藍動?！保┖炗啞丢毤彝茝V協(xié)議》。楊凌金海委托禮藍動保在中國（含香港特別行政區(qū)和澳門特別行政區(qū)）的市場化營銷渠道獨家推廣楊凌金海的口蹄疫疫苗產(chǎn)品，禮藍動保將充分發(fā)揮其資源和優(yōu)勢協(xié)助楊凌金海產(chǎn)品市場推廣。
本次楊凌金海與禮藍動?！丢毤彝茝V協(xié)議》的簽訂是海利生物國際化合作的重要舉措，楊凌金海是經(jīng)國家農(nóng)業(yè)部批準，由海利生物與阿根廷BiogénesisBagóS.A.公司共同合資興建、國內(nèi)唯一的一家中外合資的口蹄疫疫苗生產(chǎn)企業(yè)。2019年1月22日，楊凌金海獲得豬口蹄疫O型、A型二價滅活疫苗（OHM/02株+AKT-Ш株）的新獸藥證書，預計將在年內(nèi)獲得生產(chǎn)批件口蹄疫疫苗作為畜用疫苗中份額最大的單品，市場前景廣闊，本次與禮藍動保合作是結合雙方優(yōu)勢的一次“雙贏”，雙方都將致力于為中國的口蹄疫疫病預防做出積極貢獻。
關于海利生物
上海海利生物技術股份有限公司(SH:603718)是一家集研發(fā)、生產(chǎn)、銷售、服務于一體的專業(yè)化獸用生物制品生產(chǎn)企業(yè)。公司是農(nóng)業(yè)部在上海批準生產(chǎn)獸用生物制品的定點企業(yè)及農(nóng)業(yè)部在上海設立的動物重大疫情防治生產(chǎn)基地，產(chǎn)品線齊全，產(chǎn)品結構完善，具備全方位服務的產(chǎn)品基礎和能力。與此同時，公司積極開展對外投資，積極落實“動保+人保”的雙輪驅動布局：2018年全資收購了從事醫(yī)用體外診斷試劑研究、開發(fā)、和生產(chǎn)的高新技術企業(yè)上海捷門生物技術有限公司；與藥明生物合資設立了主要從事人用疫苗（包括癌癥疫苗）的CDMO業(yè)務的上海藥明海德生物科技有限公司，構建全生物產(chǎn)業(yè)鏈的布局，在更廣闊的平臺上實現(xiàn)轉型升級。
關于楊凌金海
楊凌金海生物技術有限公司是海利生物與全球最大的口蹄疫疫苗生產(chǎn)商之一的阿根廷BiogénesisBagóS.A.公司共同合資興建、國內(nèi)唯一的一家中外合資的口蹄疫疫苗生產(chǎn)企業(yè)。楊凌金海采用BB 公司最先進和最穩(wěn)定的全懸浮、高純化生產(chǎn)工藝技術進行口蹄疫疫苗的生產(chǎn)，其工藝規(guī)?；夹g水平位居全球行業(yè)前列，致力于為中國的口蹄疫疫病預防做出積極貢獻。
關于禮藍動保
禮藍動保(NYSE:ELAN）是一家國際化的動保公司，業(yè)務遍布超過90個國家，公司致力于不斷研發(fā)并生產(chǎn)高品質的產(chǎn)品并為客戶提供優(yōu)質的服務，以改善食品動物和伴侶動物的健康。傳承于64年的積淀，我們戮力創(chuàng)新，惠及客戶。同時，我們在全球擁有超過5,800名員工，我們始終秉持包容和進取的企業(yè)文化。作為禮藍人，我們心系使命—讓食品和伴侶動物不斷豐富我們的生活，使動物、人類和地球變得更健康！禮藍動保從禮來公司（EliLilly and Company）剝離后，現(xiàn)已成為一家完全獨立的上市公司。 Elanco的中文名稱現(xiàn)已變更為“禮藍（上海）動物保健有限公司”。更多信息，請查詢www.elanco.com。
Yangling Jinhai Biotechnology Co., Ltd., the majority owned subsidiary of Shanghai Hile Bio-Technology Co.,Ltd. entered into an exclusive promotion agreement with Elanco (Shanghai) Animal Health Co., Ltd.
On August 20th, 2019, Yangling Jinhai Biotechnology Co., Ltd. (“YanglingJinhai”), the majority owned subsidiary of Shanghai Hile Bio-Technology Co.,Ltd. (SH:603718) entered into an exclusive promotion agreement with Elanco (Shanghai) Animal Health Co., Ltd.(“Elanco China”), the subsidiary of Elanco US Inc. Yangling Jinhai has appointed Elanco China to exclusively promote its foot-and-mouth disease(FMD) vaccine in China (including the Hong Kong Special Administrative Region and the Macau Special Administrative Region) via private market promotion channels. Elanco China will make best use of its resources and advantages to assist in the promotion of the product of Yangling Jinhai.
The exclusive promotion agreement executed between Yangling Jinhai and Elanco China is an important step of Hile-Bio’s internationalization. Yangling Jinhai is a joint venture established by Hile-Bio and BiogénesisBagó S.A., and it is the only joint venture which produces FMD vaccine in China. On January 22, 2019,Yangling Jinhai obtained the new veterinary drug certificate for swine type O and A bivalent inactivated vaccine (OHM/02+AKT-Ш), and it is expected to obtain the manufacturing permit by the end of this year. FMD vaccine is the largest vaccine category in animal health sector with promising growth in the future. The cooperation with Elanco China is a win-win cooperation, with the advantages of both parties combined. The parties will use their best endeavors to contribute to the prevention of FMD disease in China.
About Hile
ShanghaiHile Bio-Technology Co.,Ltd. (SH:603718) is an integrated veterinary biological product company of product research and development, manufacturing, selling and technical services. Hile-Bio is the appointed enterprise of the Ministry of Agriculture to produce veterinary biological products in Shanghai. It is also the appointed manufacturing base to prevent and control major animal outbreaks. Hile-Bio has a full range of product portfolio and sound product mix, with strong capabilities of providing full services. Meanwhile, Hile-Bio is active in investment and is executing “Animal Health + Human Health” strategy. In 2018, Hile-Bio acquired JieMen Bio-Technology Co.,Ltd. which is a high-tech enterprise specializing in the product research, development, and manufacturing of medical in-vitro diagnostic reagents. Hile-Bio also established a joint venture with Wuxi Biologics specializing in CDMO business of human vaccine (including cancer vaccine). Hile-Bio is targeting at the whole biologic chain and making efforts to achieve transformation via a broader platform.
About Yangling JinHai
Yangling Jinhai Biotechnology Co., Ltd. is the joint venture of Hile-Bio with BiogénesisBagóS.A. from Argentina, one of the worldwide biggest FMD vaccine manufacturing companies. Yangling Jinhai is the only sino-foreign joint venture manufacturing FMD vaccine products in China. It adopts the most advanced and high stability level of full suspension and high purity production technologies. YanglingJinHai's production capacity and technologies both rank in the top of the industry globally and it is dedicated to FMD prevention and control.
About Elanco
Elanco (NYSE: ELAN) is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets in more than 90 countries. With a 64-year heritage, werigorously innovate to improve the health of animals and benefit our customers, while fostering an inclusive, cause-driven culture for more than 5,800 employees. At Elanco, we’re driven by our vision of food and companionship enriching life — all to advance the health of animals, people and the planet. Learn more at www.elanco.com
